IAG . Bankinter Fija su Precio Objetivo en 3,50€ Por Acción . En Marcha la Recompra de Acciones .
04 marzo 2010
Aplidn Fase II Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma .
*.- Estimated Enrollment: 58 .
*.- Study Start Date: December 2004 .
*.- Estimated Study Completion Date: March 2010 .
*.- Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure) .
Entrada más reciente
Entrada antigua
Inicio